20
Participants
Start Date
April 30, 2014
Primary Completion Date
January 31, 2016
Study Completion Date
January 31, 2016
Sitagliptin
"Week 0-16: Two 50mg tablets (or one 50mg tablet for participants with moderate kidney disease) once daily for 16 weeks during the double-blind phase.~Week 16-32: Then two 50mg tablets (or one 50mg tablet for participants with moderate kidney disease) once daily for 16 weeks during the open-label phase of the trial."
Gliclazide
"Double-blind phase (week 0-16):~One 80mg capsule once daily for 4 weeks. The if no severe hypoglycaemic episodes one 80mg capsule twice daily for 4 weeks.~Then if no severe hypoglycaemic episodes two 80mg capsules twice daily for 8 weeks."
Sitagliptin matched placebo
Week 0-16: Two tablets (or one tablet for those with moderate kidney disease) daily for 16 weeks during the double-blind phase.
Gliclazide matched placebo capsule
"Double-blind phase (week 0-16):~One capsule daily for 4 weeks. Then if no severe hypoglycaemic episodes one capsule twice daily for 4 weeks. Then if no severe hypoglycaemic episodes two capsules twice daily for 8 weeks."
The Adelaide and Meath Hospital, Dublin
UCD Clinical Research Centre, St Vincent's University Hospital,, Dublin
University College Dublin
OTHER